Mesenchymal stem/stromal cells in cancer therapy

Lan, Tu; Luo, Min; Wei, Xiawei

doi:10.1186/s13045-021-01208-w

Cited by 110 publications

(45 citation statements)

References 196 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, limited progress has been made in translational medicine due to ignorance of the contentious roles that MSC play in the interaction with malignancies. Specifically, recent evidence suggests that MSC may play a therapeutic function in lung disorders and infections (Huang 2015 ; White et al 2016 ; Cruz and Rocco 2020 ; Shi et al 2020 ; Lan et al 2021 ; Hoang et al 2022 ). Accordingly, transplantation of MSCs and MSC-derived EVs are the main RM-based auxiliary treatments for COVID-19 that have been accepted by physicians or in clinical trials.…”

Section: Therapeutic Interventionsmentioning

confidence: 99%

Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells

et al. 2023

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 has been a shocking disaster for healthcare systems worldwide since December 2019. This virus can affect all systems of the body and its symptoms vary from a simple upper respiratory infection to fatal complications including end-organ damage. On the other hand, the normal immune system plays a pivotal role in the recovery of infectious diseases such as COVID-19. However, occasionally, exaggerated immune system inflammation and an excessive synthesis of cytokines, known as a "cytokine storm," can deteriorate the patient's clinical condition. Secondary bacterial co-infection is another problem in COVID-19 which affects the prognosis of patients. Although there are a few studies about this complication, they suggest not using antibiotics commonly, especially broad-spectrum ones. During this pandemic, various approaches and therapeutics were introduced for treating COVID-19 patients. However, available treatments are not helpful enough, especially for complicated cases. Hence, in this era, cell therapy and regenerative medicine will create new opportunities. Therefore, the therapeutic benefits of mesenchymal stem cells, especially their antimicrobial activity, will help us understand how to treat COVID-19. Herein, mesenchymal stem cells may stop the immune system from becoming overactive in COVID-19 patients. On the other side, the stem cells' capacity for repair could encourage natural healing processes.

show abstract

Section: Therapeutic Interventionsmentioning

confidence: 99%

Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells

et al. 2023

View full text Add to dashboard Cite

show abstract

“…MSCs of different tissue origin have been investigated for treating several indications, including tissue injuries, autoimmune diseases, and metastatic cancer [ 41 , 42 , 43 , 44 , 45 , 46 ]. Use of both autologous and allogeneic MSCs has been investigated.…”

Section: Mesenchymal Stem Cells (Msc)mentioning

confidence: 99%

Cellular-Based Therapies in Systemic Sclerosis: From Hematopoietic Stem Cell Transplant to Innovative Approaches

Xue

Minniti

Papa

et al. 2022

Cells

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a systemic disease characterized by autoimmune responses, vasculopathy and tissue fibrosis. The pathogenic mechanisms involve a wide range of cells and soluble factors. The complexity of interactions leads to heterogeneous clinical features in terms of the extent, severity, and rate of progression of skin fibrosis and internal organ involvement. Available disease-modifying drugs have only modest effects on halting disease progression and may be associated with significant side effects. Therefore, cellular therapies have been developed aiming at the restoration of immunologic self-tolerance in order to provide durable remissions or to foster tissue regeneration. Currently, SSc is recommended as the ‘standard indication’ for autologous hematopoietic stem cell transplantation by the European Society for Blood and Marrow Transplantation. This review provides an overview on cellular therapies in SSc, from pre-clinical models to clinical applications, opening towards more advanced cellular therapies, such as mesenchymal stem cells, regulatory T cells and potentially CAR-T-cell therapies.

show abstract

“…Mesenchymal stem cells (MSC) have been described as adult multipotent stem cells, showing many relevant properties, spanning from the ability to immunomodulate and migrate to specific sites of injury to the trans-differentiation into multiple cell types [1,2]. MSC have been considered ideal candidates for many clinical and cell therapy applications, almost concluding that their wide applicability was also possible in cancer treatment [3].…”

Section: Introductionmentioning

confidence: 99%

“Remote adipose tissue-derived stromal cells of patients with lung adenocarcinoma generate a similar malignant microenvironment of the lung stromal counterpart”

Falco

Bordin

Menna³

et al. 2022

Preprint

View full text Add to dashboard Cite

Cancer alters both local and distant tissue by influencing the microenvironment. In this regard, the interplay with the stromal fraction is considered critical as this latter can either foster or hamper the progression of the disease. Accordingly, the modality by which tumor may alter distant niches of stromal cells is still unclear, expecially at early stages. In this short report we attempt to better understand the biology of this cross talk. In our autologous stromal experimental setting, we found that remote adipose tissue-derived mesenchymal stem cells (mediastinal AMSC) obtained from patients with lung adenocarcinoma sustain proliferation and clonogenic ability of A549 and human primary lung adenocarcinoma cells similarly to the autologous stromal lung counterpart (LMSC). This effect is not observed in lung benign diseases as the hamartochondroma. This finding was validated by conditioning benign AMSC with supernatants from LAC up to 21 days. The new reconditioned media of the stromal fraction so obtained, was able to increase cell proliferation of A549 cells at 14 and 21 days similarly to that derived from AMSC of patients with lung adenocarcinoma. The secretome generated by remote AMSC revealed overlapping to the corresponding malignant microenvironment of the autologous local LMSC. Among the plethora of 80 soluble factors analysed by arrays, a small pool of 5 upregulated molecules including IL1-beta;, IL-3, MCP-1, TNF-alpha and EGF, was commonly shared by both malignant-like autologous A- and LMSC derived microenvironments vs those benign. The bioinformatic analysis both revealed that these proteins were strictly and functionally interconnected to the lung fibrosis and proinflammation and that miR-126, 101, 486 and let-7-g were their main targets. Accordingly, we found that in lung cancer tissues and blood samples from the same set of patients here employed, miR-126 and miR-486 displayed the highest expression levels in tissue and blood, respectively.

show abstract

Mesenchymal stem/stromal cells in cancer therapy

Cited by 110 publications

References 196 publications

Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells

Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells

Cellular-Based Therapies in Systemic Sclerosis: From Hematopoietic Stem Cell Transplant to Innovative Approaches

“Remote adipose tissue-derived stromal cells of patients with lung adenocarcinoma generate a similar malignant microenvironment of the lung stromal counterpart”

Contact Info

Product

Resources

About